Oct 12, 2026

Featuring perspectives from Dr Meletios-Athanasios (Thanos) C Dimopoulos, Dr Robert Z Orlowski and Dr Noopur Raje, moderated by Dr Orlowski, including the following topics:

• Introduction (0:00)
• New and Emerging Strategies with Bispecific Antibodies in Multiple Myeloma (MM) — Dr Raje (2:20)
• Utility of Antibody-Drug...

Oct 10, 2026

Featuring perspectives from Dr Sara M Tolaney, including the following topics:

• Management of adverse events associated with TROP2-targeting antibody-drug conjugates (0:00)
• Managing brain metastases in triple-negative breast cancer (6:30)
• EGFR x HER3-directed bispecific antibodies for metastatic triple-negative breast...

Oct 9, 2026

Featuring perspectives from Dr Sara M Tolaney, including the following topics:

• Mechanistic effects and potential resistance mechanisms of antibody-drug conjugates (0:00)
• First-line treatment of metastatic triple-negative breast cancer (mTNBC) in patients eligible for immunotherapy (7:13)
• First-line treatment of mTNBC...

Oct 8, 2026

Featuring perspectives from Dr Catherine C Coombs and Dr Matthew S Davids, including the following topics:

• Introduction (0:00)
• Minimal Residual Disease Assays in Community-Based Practice (1:24)
• New Developments in Previously Untreated Chronic Lymphocytic Leukemia (CLL) — Dr Davids (8:12)
• Richter Transformation...

Oct 7, 2026

Featuring perspectives from Dr Joyce F Liu, Dr David M O'Malley and Dr Brian M Slomovitz, moderated by Dr O'Malley, including the following topics:

• Case: A woman in her mid 60s with Stage II uterine carcinosarcoma treated with surgery followed by paclitaxel/carboplatin, whole-pelvic radiation and vaginal...